@prefix np: . @prefix npx: . @prefix ns1: . @prefix ns2: . @prefix ns3: . @prefix orcid: . @prefix prov: . @prefix rdf: . @prefix rdfs: . @prefix sub: . @prefix this: . @prefix xsd: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { ns1:include . } sub:provenance { sub:_assertion prov:wasGeneratedBy "S&T TWOC Project - version 4", "S&T TWOC version 3" . sub:_version prov:value "2"^^xsd:integer . sub:assertion prov:generatedAtTime "2023-07-20T09:47:22.930008"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0003-4692-1377; prov:wasDerivedFrom . rdf:OBJECT rdfs:label "antivirals like remdesivir , lopinavir , ritonavir , arbidol , oseltamivir , penciclovir , favipiravir , ganciclovir , and ribavirin ;" . rdf:OBJECT-POSITION rdfs:label "(60, 66)" . rdf:PREDICATE rdfs:label "including" . rdf:PREDICATE-POSITION rdfs:label "67" . rdf:SUBJECT rdfs:label "different pharmacological groups" . rdf:SUBJECT-POSITION rdfs:label "(60, 66)" . rdf:Statement rdfs:label "Results Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy." . rdfs:ABSTRACT-UID ns2:50 "8j41d0a3" . rdfs:TRIPLE-UID ns3:8j41d0a3-TRIPLE-ABSTRACT-1 "8j41d0a3-TRIPLE-ABSTRACT-1" . rdfs:label "groups" . rdfs:label "oseltamivir" . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "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"; npx:hasSignature "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"; npx:hasSignatureTarget this: . this: prov:wasAttributedTo orcid:0000-0003-4692-1377 . }